Genentech, a member of the Roche Group, broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast.
The 700,000-square-foot facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.
The project will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during the development phase. Genentech’s initial investment in North Carolina is estimated at more than $700 million, part of a larger $50 billion commitment to President Trump’s initiatives to invest in US manufacturing, infrastructure and R&D.
The company selected Holly Springs, a growing hub for biopharmaceutical innovation, for its highly skilled local workforce, strong academic institutions and proximity to other leading life science companies in the Raleigh-Durham area.
The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The future facility will increase production capacity for the company’s manufacturing network, while enhancing supply chain resilience through a high-volume, high-efficiency yet sustainable design. The 100-acre lot includes space for future expansion.
